
Sunday, January 02, 2022 1:14:57 PM
MRNA COULD COULD GO BELOW $100 OR MORE IN 2022 !!!!!
RE;
Reviewing 12-08-2021 $ABUS/ GenevantFACTS: & $ABUS WOW FOR INFRINGEMENT OF PATENTS PFE BNTX MRNA NVAX , OTHERS CONTINUES TO GROW !!!!!
COURT DENIED $MRNA APPEAL;
https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-loses-appeal-challenging-arbutus-vaccine-patents-2021-12-01/
BUY;Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment 11-19-2021
https://seekingalpha.com/article/4470947-arbutus-biopharma-recent-acquisition-of-dicerna-makes-it-an-attractive-investment
*Arbutus shares are trading higher after The Patent Trial and Appeals Board has turned down Moderna's appeal to invalidate two of Arbutus' patents on drug-delivery technology.
Benzinga
also
12-01-2021
$ABUS Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity
December 01 2021 - 11:58AM
GlobeNewswire Inc.
Alert
Share On Facebook
https://ih.advfn.com/stock-market/NASDAQ/arbutus-biopharma-ABUS/stock-news/86700511/preliminary-data-shows-that-arbutus-capsid-inhib
ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.ABUS
1) May 4th Appeals Briefs due in MRNA vs ABUS 069. Oral next. ABUS asked for extension.
2) May 5th. HBV Virtual Summit
3) May 10ish 2021, Expected Q1 Earnings Report. Has NOT been announced but was May 11, 2020
4) NO major PR since mid March, PR challenged. Last HBV trial news was Dec. 10th, 90 days was due March 10th
5) Annual Meeting email sent April 22nd. Meeting May 23rd
6) Requested 9M shares in Comp. Plan in 2021 vs 3M in 2020.
7) Announced
$75M
Offering last meeting. ATM. At $3.75/share, that's 20,000,000 shares. Averaged 2M a month from Oct 2020 to March 2021.
OS rose from 85M to 96M
8) October 2021, MANDATORY conversion of preferred shares owned by Roivant for repayment of loan 5 years ago.
24 million shares at $7. Roivant/Vivek will then own 40M ABUS shares.
9) Oct, 2021 - 5 year "No Buy" expires. Roivant can buy ABUS shares
10) Sophie developed cure for HepC!
11) Pipeline!!! AB 729 PT COVID P1 ends 4/30
12) Gritstone
13) Genevant
AND;
$ABUS WOW FOR DIS INFRINGEMENT OF PATENTS MRNA CONTINUES TO GROW !!!!!
MRNA
MarketWatch • 2 hours ago
U.S. buys another 100 million COVID-19 vaccine candidate doses:
Moderna
IS VERY SUCCEESSFUL SO FAR IN THEIR VACCINE
Recent ABUS News
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 11/21/2023 01:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:02:39 PM
- Arbutus to Present at Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 09:18:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 12:31:16 PM
- Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/07/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 12:16:12 PM
- Arbutus Announces CEO, William Collier, to Retire December 31, 2023 • GlobeNewswire Inc. • 11/07/2023 12:15:00 PM
- Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 10/24/2023 11:30:00 AM
- Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference • GlobeNewswire Inc. • 10/18/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 12:06:11 PM
- Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023 • GlobeNewswire Inc. • 10/11/2023 12:05:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 09/11/2023 09:07:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 08:16:17 PM
- Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended • GlobeNewswire Inc. • 09/11/2023 08:15:00 PM
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 09/07/2023 11:30:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/03/2023 08:18:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/03/2023 08:10:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/03/2023 11:31:25 AM
- Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update • GlobeNewswire Inc. • 08/03/2023 11:30:00 AM
- Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 07/20/2023 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/13/2023 08:13:43 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/13/2023 08:11:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2023 08:50:46 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2023 08:48:48 PM
CGrowth Capital Inc. Sets Stage for Exciting 2024 with Savage Barbell Apparel Expansion • CGRA • Nov 28, 2023 11:15 AM
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing • IMMX • Nov 28, 2023 10:48 AM
Swifty Global Secures GLI Certification for New Cutting-Edge B2B Gaming Platform • DRCR • Nov 28, 2023 9:15 AM
Nate's Food Co. Successfully Obtains GACC Registration in China, Paving the Way for Contract Execution on Commodities • NHMD • Nov 28, 2023 8:00 AM
Mass Megawatts Announces LOWEST PRICE GUARANTEE on Solar Project Sales and Further Cost Reductions Using our Patent Pending Technologies • MMMW • Nov 28, 2023 8:00 AM
Branded Legacy Commences Buyback of 1,000,000 Preferred Class D Shares • BLEG • Nov 28, 2023 7:23 AM